volume 190, issue 10, P5216-5225 2013
DOI: 10.4049/jimmunol.1300097
View full text
Joseph Conlon, Dara L. Burdette, Shruti Sharma, Numana Bhat, Mikayla Thompson, Zhaozhao Jiang, Vijay A. K. Rathinam, Brian Monks, Tengchuan Jin, T. Sam Xiao, Stefanie N. Vogel, Russell E. Vance, Katherine A. Fitzgerald

Abstract: Vascular disrupting agents (VDAs) such as DMXAA (5,6-dimethylxanthenone-4-acetic acid) represent a novel approach for cancer treatment. DMXAA has potent anti-tumor activity in mice and, despite significant pre-clinical promise, failed human clinical trials. The anti-tumor activity of DMXAA has been linked to its ability to induce type I interferons in macrophages although the molecular mechanisms involved are poorly understood. Here we identify STING as a direct receptor for DMXAA leading to TBK1 and IRF3 sig…

expand abstract